Minerva Neuroscie Cmn (NERV) 14.31 $NERV Minerv
Post# of 273242
Posted On: 09/19/2016 7:09:46 AM
Minerva Neuroscie Cmn (NERV) 14.31 $NERV
Minerva Neurosciences to Present at 23rd Annual NewsMakers in the Biotech Industry Conference on September 9, 2016
Globe Newswire - Fri Sep 02, 7:30AM CDT
WALTHAM, Mass., Sept. 02, 2016 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today announced that it will present at the 23rd Annual NewsMakers in the Biotech Industry conference in New York on Friday, September 9, 2016 at 1:30 p.m. eastern time.
NERV: 14.31 (+0.43)
Will Minerva Neurosciences (NERV) Continue to Surge Higher?
Zacks Equity Research - Zacks Investment Research - Thu Aug 18, 9:00AM CDT
As of late, it has definitely been a great time to be an investor in Minerva Neurosciences, Inc. (NERV)
NERV: 14.31 (+0.43)
Minerva Neurosciences Reports Second Quarter 2016 Financial Results and Business Updates
GlobeNewswire - Thu Aug 04, 6:30AM CDT
Positive clinical data advance development with MIN-101 in schizophrenia and MIN-117 in major depressive disorder
NERV: 14.31 (+0.43)
Biotechnology Stocks on Investors' Radar -- Minerva Neurosciences, Portola Pharma, Trevena, and Anthera Pharma
PR Newswire - Tue Aug 02, 9:02AM CDT
The Biotech stocks are showing substantial strength as on Monday, August 01st, 2016, the NYSE Arca Biotechnology Index was up 2.7%, reaching a seven-month intra-day high. Stock-Callers.com now assesses the following equities and see how they fared at the last close: Minerva Neurosciences Inc. (NASDAQ: NERV), Portola Pharmaceuticals Inc. (NASDAQ: PTLA), Trevena Inc. (NASDAQ: TRVN), and Anthera Pharmaceuticals Inc. (NASDAQ: ANTH). Learn more about these stocks by downloading their comprehensive and free reports at:
TRVN: 7.06 (+0.09), PTLA: 23.60 (+0.57), ANTH: 3.06 (-0.23), NERV: 14.31 (+0.43)
Minerva Neurosciences to Report Second Quarter 2016 Financial Results and Business Updates on August 4, 2016
Globe Newswire - Thu Jul 28, 7:30AM CDT
Management to host conference call
NERV: 14.31 (+0.43)
Biotechnology Stocks in Motion -- Minerva Neurosciences, Portola Pharma, Trevena, and Anthera Pharma
PR Newswire - Wed Jun 22, 7:20AM CDT
On Tuesday, June 21, 2016, the NASDAQ Composite ended the trading session at 4,843.76, up 0.14%; the Dow Jones Industrial Average advanced 0.14% to finish at 17,829.73; and the S&P 500 closed at 2,088.90, up 0.27%. The gains were broad based as five out of nine sectors ended the session in positive. Stock-Callers.com has initiated coverage on the following equities: Minerva Neurosciences Inc. (NASDAQ: NERV), Portola Pharmaceuticals Inc. (NASDAQ: PTLA), Trevena Inc. (NASDAQ: TRVN), and Anthera Pharmaceuticals Inc. (NASDAQ: ANTH). Learn more about these stocks by accessing their free trade alerts at:
TRVN: 7.06 (+0.09), PTLA: 23.60 (+0.57), ANTH: 3.06 (-0.23), NERV: 14.31 (+0.43)
Minerva Neurosciences to Present at JMP Securities Life Sciences Conference June 21, 2016
Globe Newswire - Tue Jun 14, 3:15PM CDT
WALTHAM, Mass., June 14, 2016 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today announced that it will present at the JMP Securities Life Sciences Conference in New York on Tuesday, June 21 at 12:30 p.m. eastern time.
NERV: 14.31 (+0.43)
Minerva Neurosciences Announces Pricing of Public Offering of Common Stock
GlobeNewswire - Tue Jun 14, 8:05AM CDT
Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company, today announced the pricing of an underwritten public offering of 5,263,158 shares of its common stock at a price to the public of $9.50 per share. Proceeds to Minerva from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be approximately $50.0 million. The offering is expected to close on or about June 17, 2016, subject to customary closing conditions.
NERV: 14.31 (+0.43)
Minerva Neurosciences Announces Proposed Public Offering of Common Stock
Globe Newswire - Mon Jun 13, 3:01PM CDT
WALTHAM, Mass., June 13, 2016 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company, today announced its intention to offer and sell shares of its common stock in an underwritten public offering pursuant to an existing shelf registration statement. All of the shares in the proposed offering are to be sold by Minerva. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.
NERV: 14.31 (+0.43)
Minerva Neurosciences to Present at Jefferies 2016 Healthcare Conference on June 8, 2016
Globe Newswire - Wed Jun 01, 7:31AM CDT
WALTHAM, Mass., June 01, 2016 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today announced that it will present at the Jefferies 2016 Healthcare Conference on June 8, 2016 at 11:00 a.m. Eastern Time.
NERV: 14.31 (+0.43)
Minerva Surges on Positive Results on Depression Candidate
Zacks Equity Research - Zacks Investment Research - Fri May 27, 5:48AM CDT
Shares of Minerva Neurosciences, Inc. (NERV) soared 233.3% after the company announced positive top-line results from a phase IIa trial on antidepressant drug candidate, MIN-117
JNJ: 118.25 (-0.38), NERV: 14.31 (+0.43), PFE: 33.94 (-0.20), BMY: 55.60 (-0.37)
Minerva Neurosciences Announces Positive Results in Phase IIA Trial of MIN-117 in Major Depressive Disorder
Globe Newswire - Thu May 26, 7:15AM CDT
MIN-117 meets primary and secondary endpoints
NERV: 14.31 (+0.43)
Minerva Neurosciences Announces Positive Results From Phase IIB Trial of MIN-101 Monotherapy in Schizophrenia
Globe Newswire - Thu May 26, 7:00AM CDT
MIN-101 meets primary and secondary endpoints
NERV: 14.31 (+0.43)
Minerva Neurosciences reports 1Q loss
Automated Insights - Tue May 03, 6:44AM CDT
WALTHAM, Mass. (AP) _ Minerva Neurosciences Inc. (NERV) on Tuesday reported a loss of $8 million in its first quarter.
NERV: 14.31 (+0.43)
Minerva Neurosciences to Present at 23rd Annual NewsMakers in the Biotech Industry Conference on September 9, 2016
Globe Newswire - Fri Sep 02, 7:30AM CDT
WALTHAM, Mass., Sept. 02, 2016 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today announced that it will present at the 23rd Annual NewsMakers in the Biotech Industry conference in New York on Friday, September 9, 2016 at 1:30 p.m. eastern time.
NERV: 14.31 (+0.43)
Will Minerva Neurosciences (NERV) Continue to Surge Higher?
Zacks Equity Research - Zacks Investment Research - Thu Aug 18, 9:00AM CDT
As of late, it has definitely been a great time to be an investor in Minerva Neurosciences, Inc. (NERV)
NERV: 14.31 (+0.43)
Minerva Neurosciences Reports Second Quarter 2016 Financial Results and Business Updates
GlobeNewswire - Thu Aug 04, 6:30AM CDT
Positive clinical data advance development with MIN-101 in schizophrenia and MIN-117 in major depressive disorder
NERV: 14.31 (+0.43)
Biotechnology Stocks on Investors' Radar -- Minerva Neurosciences, Portola Pharma, Trevena, and Anthera Pharma
PR Newswire - Tue Aug 02, 9:02AM CDT
The Biotech stocks are showing substantial strength as on Monday, August 01st, 2016, the NYSE Arca Biotechnology Index was up 2.7%, reaching a seven-month intra-day high. Stock-Callers.com now assesses the following equities and see how they fared at the last close: Minerva Neurosciences Inc. (NASDAQ: NERV), Portola Pharmaceuticals Inc. (NASDAQ: PTLA), Trevena Inc. (NASDAQ: TRVN), and Anthera Pharmaceuticals Inc. (NASDAQ: ANTH). Learn more about these stocks by downloading their comprehensive and free reports at:
TRVN: 7.06 (+0.09), PTLA: 23.60 (+0.57), ANTH: 3.06 (-0.23), NERV: 14.31 (+0.43)
Minerva Neurosciences to Report Second Quarter 2016 Financial Results and Business Updates on August 4, 2016
Globe Newswire - Thu Jul 28, 7:30AM CDT
Management to host conference call
NERV: 14.31 (+0.43)
Biotechnology Stocks in Motion -- Minerva Neurosciences, Portola Pharma, Trevena, and Anthera Pharma
PR Newswire - Wed Jun 22, 7:20AM CDT
On Tuesday, June 21, 2016, the NASDAQ Composite ended the trading session at 4,843.76, up 0.14%; the Dow Jones Industrial Average advanced 0.14% to finish at 17,829.73; and the S&P 500 closed at 2,088.90, up 0.27%. The gains were broad based as five out of nine sectors ended the session in positive. Stock-Callers.com has initiated coverage on the following equities: Minerva Neurosciences Inc. (NASDAQ: NERV), Portola Pharmaceuticals Inc. (NASDAQ: PTLA), Trevena Inc. (NASDAQ: TRVN), and Anthera Pharmaceuticals Inc. (NASDAQ: ANTH). Learn more about these stocks by accessing their free trade alerts at:
TRVN: 7.06 (+0.09), PTLA: 23.60 (+0.57), ANTH: 3.06 (-0.23), NERV: 14.31 (+0.43)
Minerva Neurosciences to Present at JMP Securities Life Sciences Conference June 21, 2016
Globe Newswire - Tue Jun 14, 3:15PM CDT
WALTHAM, Mass., June 14, 2016 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today announced that it will present at the JMP Securities Life Sciences Conference in New York on Tuesday, June 21 at 12:30 p.m. eastern time.
NERV: 14.31 (+0.43)
Minerva Neurosciences Announces Pricing of Public Offering of Common Stock
GlobeNewswire - Tue Jun 14, 8:05AM CDT
Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company, today announced the pricing of an underwritten public offering of 5,263,158 shares of its common stock at a price to the public of $9.50 per share. Proceeds to Minerva from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be approximately $50.0 million. The offering is expected to close on or about June 17, 2016, subject to customary closing conditions.
NERV: 14.31 (+0.43)
Minerva Neurosciences Announces Proposed Public Offering of Common Stock
Globe Newswire - Mon Jun 13, 3:01PM CDT
WALTHAM, Mass., June 13, 2016 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company, today announced its intention to offer and sell shares of its common stock in an underwritten public offering pursuant to an existing shelf registration statement. All of the shares in the proposed offering are to be sold by Minerva. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.
NERV: 14.31 (+0.43)
Minerva Neurosciences to Present at Jefferies 2016 Healthcare Conference on June 8, 2016
Globe Newswire - Wed Jun 01, 7:31AM CDT
WALTHAM, Mass., June 01, 2016 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today announced that it will present at the Jefferies 2016 Healthcare Conference on June 8, 2016 at 11:00 a.m. Eastern Time.
NERV: 14.31 (+0.43)
Minerva Surges on Positive Results on Depression Candidate
Zacks Equity Research - Zacks Investment Research - Fri May 27, 5:48AM CDT
Shares of Minerva Neurosciences, Inc. (NERV) soared 233.3% after the company announced positive top-line results from a phase IIa trial on antidepressant drug candidate, MIN-117
JNJ: 118.25 (-0.38), NERV: 14.31 (+0.43), PFE: 33.94 (-0.20), BMY: 55.60 (-0.37)
Minerva Neurosciences Announces Positive Results in Phase IIA Trial of MIN-117 in Major Depressive Disorder
Globe Newswire - Thu May 26, 7:15AM CDT
MIN-117 meets primary and secondary endpoints
NERV: 14.31 (+0.43)
Minerva Neurosciences Announces Positive Results From Phase IIB Trial of MIN-101 Monotherapy in Schizophrenia
Globe Newswire - Thu May 26, 7:00AM CDT
MIN-101 meets primary and secondary endpoints
NERV: 14.31 (+0.43)
Minerva Neurosciences reports 1Q loss
Automated Insights - Tue May 03, 6:44AM CDT
WALTHAM, Mass. (AP) _ Minerva Neurosciences Inc. (NERV) on Tuesday reported a loss of $8 million in its first quarter.
NERV: 14.31 (+0.43)
(0)
(0)Scroll down for more posts ▼